Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.21K$2.21Kderived+7.2% vs Q4 2019 Net Income-$731.73K-$731.73KderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$670,713N/M Operating Cash Flowderived-$713,959N/M Margins · derivedOperating margin-30390.3%+17216.5 pt vs Q4 2019
Net margin-33154.9%+34545.4 pt vs Q4 2019
ended Aug 31, 2020 · filed Nov 4, 2020 · 65 d after period end